Publications by authors named "V S Hegade"
Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?
Can J Gastroenterol Hepatol
December 2022
Background And Aims: A third of patients with primary biliary cholangitis (PBC) experience poorly understood cognitive symptoms, with a significant impact on quality of life (QOL), and no effective medical treatment. Allopregnanolone, a neurosteroid, is a positive allosteric modulator of gamma-aminobutyricacid-A (GABA-A) receptors, associated with disordered mood, cognition, and memory. This study explored associations between allopregnanolone and a disease-specific QOL scoring system (PBC-40) in PBC patients.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied how well special metal tubes called IDSEMS work to help people who had liver transplants and are having trouble with their bile ducts.
- They looked at data from 162 patients treated across nine hospitals in the UK, focusing on how the patients responded to the treatment over time.
- The findings showed that most patients (81%) had their problems completely fixed, but some had issues again after the treatment ended, and a few experienced complications like infections.
UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis.
Clin Gastroenterol Hepatol
June 2023
Background & Aims: Thirty-to-forty percent of patients with primary biliary cholangitis inadequately respond to ursodeoxycholic acid. Our aim was to assemble national, real-world data on the effectiveness of obeticholic acid (OCA) as a second-line treatment, alongside non-licensed therapy with fibric acid derivatives (bezafibrate or fenofibrate).
Methods: This was a nationwide observational cohort study conducted from August 2017 until June 2021.
Objective: There is a paucity of studies in the literature body evaluating short term outcomes following endoscopic retrograde cholangiopancreatography (ERCP) in patients with inoperable malignant hilar biliary obstruction (MHBO). We aimed to primarily evaluate 30-day mortality in these patients and secondarily, conduct a systematic review of studies reporting 30-day mortality.
Design: We conducted a retrospective analysis of all patients with inoperable MHBO who underwent ERCP at Leeds Teaching Hospitals NHS Trust between February 2015 and September 2020.